DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Placebo-controlled Study to Investigate the Safety, and Pharmacokinetics of Oral GSK626616AC in Healthy Subjects

Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy Subjects; Anaemia

Intervention: GSK626616, placebo, midazolam (Drug); omeprazole, caffeine, flurbiprofen, rosiglitazone (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: GlaxoSmithKline

Official(s) and/or principal investigator(s):
GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline

Summary

This is a first time in human study to investigate the safety of GSK626616AC given as oral single and repeat doses in healthy subjects. An additional group of subjects will be assessed to determine the effect of several drugs given at the same time as GSK626616.

Clinical Details

Official title: A Randomized, Blinded, Placebo-controlled Study to Investigate the Safety, and Pharmacokinetics of Single and Repeat Dose Escalation of the Oral YAK3/DYRK3 Inhibitor GSK626616AC in Healthy Subjects

Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment

Primary outcome:

adverse events at end of each cohort

hematology/chemistry/urinalysis at end of each cohort

physical examination at end of each cohort

vital signs and electrocardiogram (ECG) at end of each cohort

Secondary outcome:

GSK626616 pharmacokinetics at end of each cohort

hemoglobin at end of each cohort

red blood cell measurements at end of each cohort

estimates of CYP enzyme activity at end of study

mRNA levels in peripheral blood at end of study

Eligibility

Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Age 18 to 55 years healthy subjects

- Hemoglobin values of 13. 5-17. 0 g/dL for males or 12. 0-15. 5 g/dL for females.

- Females cannot be pregnant.

Exclusion Criteria:

- Cannot have exposure to greater than 4 new chemical entities within 12 months.

- Cannot have a clinical history of current alcohol, or illicit drug use which, in the

judgment of the Investigator, would interfere with the subject's ability to comply with the dosing schedule.

- Cannot have a history of regular use of tobacco- or nicotine-containing products

within 3 months.

- Must not have received a blood transfusion or had a donation of blood within 3 months

prior to study entry.

- Cannot use be taking prescription, non-prescription or illicit drugs.

Locations and Contacts

GSK Investigational Site, Randwick, Sydney, New South Wales 2031, Australia

GSK Investigational Site, Herston, Queensland 4006, Australia

GSK Investigational Site, Adelaide, South Australia 5000, Australia

Additional Information

Starting date: November 2006
Last updated: March 15, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017